This phase II/III trial studies how well 18F-DCFPyL PSMA-PET imaging works in detecting early prostate cancer that has spread to other places in the body (metastatic) in patients with high GC test scores. Diagnostic procedures such as 18F-DCFPyL PSMA-PET imaging, may improve the ability to detect early metastatic disease in prostate cancer patients with a high GC and ultimately help doctors in planning the optimal course of treatment for the disease.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03495427.
Locations matching your search criteria
United States
Florida
Tampa
Moffitt Cancer CenterStatus: Active
Contact: Kosj Yamoah
Phone: 813-745-8424
PRIMARY OBJECTIVE:
I. To estimate the concordance between tumor genomic classifier (GC) risk score and early metastatic disease using prostate specific membrane antigen (PSMA)-positron emission tomography (PET) imaging.
SECONDARY OBJECTIVE:
I. To validate the GC as a predictor of 5-year metastatic disease post-treatment using PSMA-PET imaging.
OUTLINE:
Beginning at least 2 years post-treatment, patients receive fluorine F 18 DCFPyL intravenously (IV), then undergo PSMA-PET scan over 30-45 minutes yearly for at least 5 years post-treatment.
Lead OrganizationMoffitt Cancer Center
Principal InvestigatorKosj Yamoah
